Atrix regulatory update

ATRX received received FDA marketing approval for its Atridox doxycycline hyclate 10 percent site-specific antibiotic to treat periodontal disease.

The company also received 510(k) clearance from the FDA for its Atrisorb FreeFlow GTR Barrier, which is used in guided tissue regeneration therapy for severe periodontal disease. Block Drug Corp. (Jersey City, N.J.) will exclusively market Atrisorb FreeFlow in the U.S. and Canada. ...